TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35800292

Group type: EXPERIMENTAL
Intervention: Denosumab (DB group; 120 mg once every 4 weeks with loading doses of 120 mg on days 8 and 15; n = 80)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Zoledronic acid (ZA group; 4 mg once every 4 weeks; n = 80)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Denosumab (DB group)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Zoledronic acid (ZA group)
Number of subjects: 160
Study: 33890144

Group type: COMPARATOR
Intervention: Group 60 (SWL frequency: 60 SWs/min)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Group 90 (SWL frequency: 90 SWs/min)
Number of subjects: 71
Study: 33054934

Group type: EXPERIMENTAL
Intervention: Bandwagon-based statement (N=80)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Testimonial-based statement (N=80)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Positive framing (N=80)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Negative framing (N=80)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Comparative advertising (N=80)
Number of subjects: 400
Study: 36233606

Group type: EXPERIMENTAL
Intervention: Relaxing algorithmic music
Number of subjects: 22

Group type: COMPARATOR
Intervention: Activating algorithmic music
Number of subjects: 22
Study: 32993338

Group type: EXPERIMENTAL
Intervention: Corticosteroid (CS) in periarticular injection
Number of subjects: 187

Group type: COMPARATOR
Intervention: No corticosteroid (no-CS) in periarticular injection
Number of subjects: 187
Study: 36192738

Group type: EXPERIMENTAL
Intervention: Home stretching exercises with spinal manipulative therapy
Number of subjects: 127

Group type: COMPARATOR
Intervention: Home stretching exercises alone
Number of subjects: 127
Study: 32981083

Group type: EXPERIMENTAL
Intervention: Parenting intervention program (8-week duration)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 79
Study: 32583567

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (arm A)
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Perioperative S‐1 plus oxaliplatin (SOX, arm B)
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Perioperative capecitabine plus oxaliplatin (XELOX, arm C)
Number of subjects: 749
Study: 36156308

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (video telemedicine contacts at 3, 6, and 9 months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 24
Study: 33522701

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise group (n = 68)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Non-exercising group (n = 60)
Number of subjects: 128
Study: 34371883

Group type: EXPERIMENTAL
Intervention: Metformin plus BHC (berberine, hesperidin, and chromium picolinate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin only (control group)
Number of subjects: 0
Study: 33038320

Group type: EXPERIMENTAL
Intervention: Healthy Stores 2020 strategy (intervention group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual retail practice (control group)
Number of subjects: 20
Study: 33686137

Group type: EXPERIMENTAL
Intervention: Visually impaired individuals
Number of subjects: 11030

Group type: EXPERIMENTAL
Intervention: Mildly visually impaired individuals
Number of subjects: 11030

Group type: EXPERIMENTAL
Intervention: Severely visually impaired individuals
Number of subjects: 11030

Group type: COMPARATOR
Intervention: Non-visually impaired individuals
Number of subjects: 11030
Study: 32660675

Group type: EXPERIMENTAL
Intervention: Combined anthocyanins and bromelain supplement (BE)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 35027477

Group type: EXPERIMENTAL
Intervention: Intrathecal 2-chloroprocaine 1% (27.8 mg estimated ED90 in cohort I, 28 mg fixed dose in cohort II)
Number of subjects: 90
Study: 32678299

Group type: EXPERIMENTAL
Intervention: Foot and back massage (6 sessions of 30 min, twice weekly for 3 weeks)
Number of subjects: 90
Study: 35340044

Group type: EXPERIMENTAL
Intervention: Combination treatment with potent topical corticosteroid (TCS) and handheld narrowband ultraviolet B
Number of subjects: 0
Study: 34639418

Group type: EXPERIMENTAL
Intervention: Specific core stability group (SCS; n = 7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: General core stability group (GCS; n = 7)
Number of subjects: 14
Study: 35064741

Group type: EXPERIMENTAL
Intervention: Isha Upa Yoga
Number of subjects: 679

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 679
Study: 33045126

Group type: EXPERIMENTAL
Intervention: Mulligan's mobilization with movement (MWM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard post-operative rehabilitation program
Number of subjects: 0
Study: 32418143

Group type: EXPERIMENTAL
Intervention: Co‐Plavix® (fixed‐dose combination of 100 mg acetylsalicylic acid and 75 mg clopidogrel)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Reference formulations (coadministration of individual formulations of 100 mg acetylsalicylic acid and 75 mg clopidogrel)
Number of subjects: 171
Study: 35699476

Group type: EXPERIMENTAL
Intervention: Teacher-delivered growth-mindset intervention
Number of subjects: 1996

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 1996
Study: 33470369

Group type: EXPERIMENTAL
Intervention: 0.5% alcoholic chlorhexidine
Number of subjects: 70

Group type: COMPARATOR
Intervention: 70% hydrated ethyl alcohol
Number of subjects: 70
Study: 32948800

Group type: EXPERIMENTAL
Intervention: High intensity exercise
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 15
Study: 36174958

Group type: EXPERIMENTAL
Intervention: Phase 2 trial with randomized evaluation of multiple doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phase 3 trial with selected dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation studies
Number of subjects: 0
Study: 33023852

Group type: EXPERIMENTAL
Intervention: Great Taste Less Waste (GTLW) intervention
Number of subjects: 502

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 502
Study: 36322594

Group type: EXPERIMENTAL
Intervention: Virtual Reality Treadmill Training (VRTT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional Treadmill Training (CTT)
Number of subjects: 60
Study: 33923462

Group type: EXPERIMENTAL
Intervention: B.strong training program
Number of subjects: 1150
Study: 34488824

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (1-hour sessions, twice a week for 12 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham (minimal) acupuncture (1-hour sessions, twice a week for 12 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham (minimal) acupuncture
Number of subjects: 90
Study: 32470139

Group type: EXPERIMENTAL
Intervention: IVP piperacillin/tazobactam
Number of subjects: 1813
Study: 36062831

Group type: EXPERIMENTAL
Intervention: EMDR treatment (weekly for 3 to 9 months)
Number of subjects: 24
Study: 616356781

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg daily for six weeks (Group A)
Number of subjects: 115

Group type: COMPARATOR
Intervention: No finasteride (Group B)
Number of subjects: 115
Study: 35578245

Group type: EXPERIMENTAL
Intervention: Secukinumab 150/300 mg
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo (switched to secukinumab at week 24)
Number of subjects: 204
Study: 34922565

Group type: EXPERIMENTAL
Intervention: Gasless laparoscopic surgery (GLS)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 105
Study: 33372125

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy (MBCT‐C)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Group Therapy (GT)
Number of subjects: 52
Study: 33974623

Group type: EXPERIMENTAL
Intervention: Urinary schistosomiasis (Schistosoma haematobium infection)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intestinal schistosomiasis (Schistosoma mansoni infection)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: S. haematobium infection
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Macrohaematuria and microhaematuria
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Risk factors for S. haematobium infection
Number of subjects: 200
Study: 32530552

Group type: EXPERIMENTAL
Intervention: Children with cystic fibrosis (CF) aged 13 to 18 years
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Mothers of children with cystic fibrosis (CF)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Mothers of children with cystic fibrosis (CF) whose children had chronic Pseudomonas infection
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Mothers of children with cystic fibrosis (CF) after the teleconference interview
Number of subjects: 135

Group type: COMPARATOR
Intervention: Healthy children aged 13 to 18 years
Number of subjects: 135
Study: 36289153

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus GG)
Number of subjects: 2650

Group type: COMPARATOR
Intervention: Usual care (without probiotics)
Number of subjects: 2650
Study: 32753339

Group type: EXPERIMENTAL
Intervention: COSMOS intervention (Communication, Systematic pain management, Medication reviews, Organization of activities, Safety)
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: COSMOS intervention
Number of subjects: 723

Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 723
Study: 35068087

Group type: EXPERIMENTAL
Intervention: 120 mg/d ifenprodil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60 mg/d ifenprodil
Number of subjects: 0
Study: 34849615

Group type: EXPERIMENTAL
Intervention: Favipiravir plus standard care
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 500
Study: 36294315

Group type: EXPERIMENTAL
Intervention: Kinesio tape (KT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sham tape (ST)
Number of subjects: 55
Study: 32683574

Group type: EXPERIMENTAL
Intervention: Households experiencing IPV and food insecurity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal alcohol use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal depressed mood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Geriatric pregnancy (age 35 or older)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal HIV status
Number of subjects: 0
Study: 33049424

Group type: EXPERIMENTAL
Intervention: Ongoing-Threat
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Prior-Threat
Number of subjects: 90

Group type: COMPARATOR
Intervention: No-Threat
Number of subjects: 90
Study: 35255220

Group type: EXPERIMENTAL
Intervention: Peer-led social marketing intervention
Number of subjects: 392

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 392
Study: 32008296

Group type: EXPERIMENTAL
Intervention: Resting heart rate increases (per 5 beats/minutes)
Number of subjects: 10212

Group type: COMPARATOR
Intervention: Resting heart rate <70 beats/minutes (control group)
Number of subjects: 10212

Group type: EXPERIMENTAL
Intervention: Increased resting heart rate in women <60 years
Number of subjects: 10212

Group type: EXPERIMENTAL
Intervention: Increased resting heart rate in women ≥60 years
Number of subjects: 10212

Group type: EXPERIMENTAL
Intervention: Resting heart rate
Number of subjects: 10212
Study: 34391233

Group type: EXPERIMENTAL
Intervention: Whole-body vibration exercise (WBVE)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Isometry group
Number of subjects: 21
Study: 32889413

Group type: EXPERIMENTAL
Intervention: Individualized goal-directed therapy (GDT)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Individualized targets (irrespective of intervention)
Number of subjects: 146
Study: 35325870

Group type: EXPERIMENTAL
Intervention: Foot massage
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 80
Study: 33587439

Group type: EXPERIMENTAL
Intervention: Doravirine/lamivudine/tenofovir (DOR/3TC/TDF)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF)
Number of subjects: 86
Study: 35605652

Group type: EXPERIMENTAL
Intervention: Polygenic risk score (PGS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA)
Number of subjects: 0
Study: 32557506

Group type: EXPERIMENTAL
Intervention: 1× PPI (Pantoprazole 40 mg 1×/day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 2× PPI (Pantoprazole 40 mg 2×/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (after PPI therapy)
Number of subjects: 39
Study: 36414172

Group type: EXPERIMENTAL
Intervention: PRP+HA injection following arthrocentesis
Number of subjects: 3

Group type: COMPARATOR
Intervention: PRP injection following arthrocentesis
Number of subjects: 3

Group type: COMPARATOR
Intervention: HA injection following arthrocentesis
Number of subjects: 3
Study: 32880220

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (0.45 mg/day) with progesterone (200 mg/day for 12 days/month)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal 17β‐estradiol (50 µg/day) with progesterone (200 mg/day for 12 days/month)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo pills and patches
Number of subjects: 0
Study: 32665311

Group type: EXPERIMENTAL
Intervention: Buparlisib (80 mg) plus carboplatin (AUC=5 every 3 weeks)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Buparlisib (60 mg) plus lomustine (100 mg/m2 every 6 weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Buparlisib (80 mg or 100 mg) plus carboplatin or buparlisib (60 mg) plus lomustine
Number of subjects: 35
Study: 34756937

Group type: EXPERIMENTAL
Intervention: Positive facial expressions (FEs) while eating raw broccoli
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Neutral facial expressions (FEs) while eating raw broccoli
Number of subjects: 111

Group type: COMPARATOR
Intervention: Non-food control video
Number of subjects: 111
Study: 35636766

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No preparation (NMBP)
Number of subjects: 120
Study: 34481464

Group type: EXPERIMENTAL
Intervention: Option B+ ART initiation
Number of subjects: 532

Group type: COMPARATOR
Intervention: Non-disclosure of HIV status
Number of subjects: 532
Study: 32363552

Group type: EXPERIMENTAL
Intervention: Antrostomy placed close to the base of the sinus floor (group base)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Antrostomy placed 3-4 mm cranially to the sinus floor (group standard)
Number of subjects: 24
Study: 33882864

Group type: EXPERIMENTAL
Intervention: CRADLE Vital Signs Alert Device
Number of subjects: 536223

Group type: COMPARATOR
Intervention: Control period (no intervention)
Number of subjects: 536223
Study: 32503359

Group type: EXPERIMENTAL
Intervention: Lumbar diagnostic facet joint nerve blocks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cervical diagnostic facet joint nerve blocks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thoracic diagnostic facet joint nerve blocks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lumbar radiofrequency ablation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic lumbar facet joint nerve blocks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cervical radiofrequency ablation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic cervical facet joint nerve blocks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thoracic therapeutic facet joint nerve blocks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thoracic intraarticular facet joint injections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avoidance of opioid analgesics during diagnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate sedation for therapeutic interventions
Number of subjects: 0
Study: 34371806

Group type: EXPERIMENTAL
Intervention: HMB (3 g/day for 12 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (sorbitol powder)
Number of subjects: 24
Study: 33176418

Group type: EXPERIMENTAL
Intervention: Intradiscal oxygen-ozone gas mixture injection
Number of subjects: 200
Study: 34384109

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 32462979

Group type: EXPERIMENTAL
Intervention: umeclidinium/vilanterol (UMEC/VI)
Number of subjects: 2425

Group type: COMPARATOR
Intervention: umeclidinium
Number of subjects: 2425

Group type: COMPARATOR
Intervention: salmeterol
Number of subjects: 2425
Study: 35435425

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2 mL of normal saline
Number of subjects: 50
Study: 34543613

Group type: EXPERIMENTAL
Intervention: Letrozole for 5 years (extended group)
Number of subjects: 2056

Group type: COMPARATOR
Intervention: Letrozole for 2-3 years (control group)
Number of subjects: 2056

Group type: EXPERIMENTAL
Intervention: Adverse events in extended group
Number of subjects: 2056

Group type: COMPARATOR
Intervention: Adverse events in control group
Number of subjects: 2056
Study: 32248638

Group type: EXPERIMENTAL
Intervention: Biobehavioral intervention (12 weekly, 30-minute telehealth sessions)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Attention control telehealth phase (GROUP2 during weeks 1-12)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Biobehavioral intervention
Number of subjects: 31
Study: 34348349

Group type: EXPERIMENTAL
Intervention: BL algae containing serum
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 60
Study: 33706052

Group type: EXPERIMENTAL
Intervention: Intraoral negative air pressure device (iNAP)
Number of subjects: 34
Study: 34567487

Group type: EXPERIMENTAL
Intervention: Laparoscopic local gastrectomy (observation group)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Radical gastrectomy for benign tumor under laparoscopy (control group)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both groups (CEA and CRP levels)
Number of subjects: 86
Study: 36189633

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 10% α‐tocopherol
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 1% quercetin
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 96
Study: 33642330

Group type: EXPERIMENTAL
Intervention: DEX (intravenous injection; 0.5 μg/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: LID (1.5 mg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: PBO (10 mL normal saline)
Number of subjects: 120
Study: 32505213

Group type: EXPERIMENTAL
Intervention: G-CHOP
Number of subjects: 1414

Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 1414
Study: 34077602

Group type: EXPERIMENTAL
Intervention: Combined self‐management and exercise programme (treatment group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Educational programme (control group)
Number of subjects: 80
Study: 34365959

Group type: EXPERIMENTAL
Intervention: Prefrontal Cortex Transcranial direct current stimulation (tDCS) on left dorsolateral prefrontal cortex
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Prefrontal Cortex Transcranial direct current stimulation (tDCS) on left orbitofrontal cortex
Number of subjects: 225

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 225
Study: 35690997

Group type: EXPERIMENTAL
Intervention: Topical acetylhexapeptide-8 (AH8) 10% lotion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control vehicle lotion
Number of subjects: 0
Study: 33401024

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) with adjunct photodynamic therapy (PDT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone (Control)
Number of subjects: 30
Study: 32073177

Group type: EXPERIMENTAL
Intervention: MDMA (75-125 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo/active control (0-40 mg of MDMA)
Number of subjects: 60
Study: 35915477

Group type: EXPERIMENTAL
Intervention: High-frequency vibration associated with cryotherapy for 30 s before and during vaccine administration
Number of subjects: 350

Group type: COMPARATOR
Intervention: Standard protocol of vaccine administration (Control group)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: High-frequency vibration associated with cryotherapy
Number of subjects: 350
Study: 34083744

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone/bupropion (NB)
Number of subjects: 1317

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 1317
Study: 32093546

Group type: EXPERIMENTAL
Intervention: Systematic Self‐reflection intervention
Number of subjects: 121

Group type: COMPARATOR
Intervention: Disengagement control group
Number of subjects: 121
Study: 34259193

Group type: EXPERIMENTAL
Intervention: Sequential therapy (SQT): esomeprazole 20 mg twice daily for 10 days, amoxicillin 1000 mg twice daily for 5 days, clarithromycin 500 mg and tinidazole 500 mg twice daily for 5 days
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard triple therapy (STT): esomeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 14 days
Number of subjects: 170
Study: 32785636

Group type: EXPERIMENTAL
Intervention: Ketamine (0.1, 0.2, 0.3, 0.4, or 0.5 mg/kg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ketamine (any dose)
Number of subjects: 38
Study: 36302533

Group type: EXPERIMENTAL
Intervention: Edaravone combined with DL-3-N-butylphthalide (NBP)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Edaravone only
Number of subjects: 86
Study: 32870473

Group type: EXPERIMENTAL
Intervention: Atezolizumab combined with nanoparticle albumin‐bound (nab)‐paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study: 34037740

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 36380519

Group type: EXPERIMENTAL
Intervention: Modified Motivational Interviewing (MMI) intervention
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94